Clinical trials: Cephalalgia
Migraine Disorders
Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers
The primary objective is to compare the pharmacokinetics (PK) profiles among five NP101 patches in healthy volunteers. The secondary objective is to evaluate the safety of NP101 in healthy volunteers.
- Trial name
- NP101-006 (NCT00720018)
- Testing
- NP101 Sumatriptan Iontophoretic Transdermal Patch
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- NuPathe Inc.
Migraine Disorders
Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine
This study is an open-label extension study to evaluate the safety, tolerability and efficacy of BOTOX® as headache prophylaxis in Chinese patients with chronic migraine who have successfully completed the double-blind study…
- Trial name
- NCT03193359
- Testing
- botulinum toxin Type A
- Sponsor
- Allergan
Migraine, Episodic Migraine
Transnasal Cooling for Migraine
This is a prospective, double-blind, sham-controlled, randomized study to assess the safety, tolerability, and optimal dose of the COOLSTAT Transnasal Thermal Regulating Device for acute treatment of migraine.
- Conditions
- Migraine, Episodic Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT04936061
- Testing
- CoolStat active device
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- CoolTech LLC
Epilepsy
A Study of the Prevalence of Headache in Epileptic Patients
The purpose of this study is to investigate the prevalence, characteristics and classification of headaches in epileptic patients.
- Trial name
- NCT00277368
- Testing
- A structured questionnaire for seizure-related headache
- Volunteers
- 719 people
- Sponsor
- Janssen Korea, Ltd., Korea
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
This is a 60 week study including a double-blind phase followed by an open-label extension phase.
- Trial name
- NCT00156910
- Testing
- Botulinum Toxin Type A
- Where
- 2 sites in United States, Canada
- Volunteers
- 679 people
- Sponsor
- Allergan
Migraine Disorders
Drug Use Investigation for IMIGRAN Tablet
The study is designed to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy of sumatriptan…
- Trial name
- NCT01376141
- Testing
- Sumatriptan
- Volunteers
- 3,571 people
- Sponsor
- GlaxoSmithKline
Low Back Pain, Migraine
Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.
- Conditions
- Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
- Trial name
- NCT00228605
- Testing
- OraVescent Fentanyl
- Where
- 38 sites in United States
- Volunteers
- 500 people
- Sponsor
- Cephalon
Migraine
Real World Effectiveness of Eptinezumab in Participants With Migraine
The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM).
- Trial name
- EVEC (NCT05284019)
- Testing
- Eptinezumab, Erenumab, Onabotulinumtoxin-A
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- H. Lundbeck A/S
Migraine Headache
Neurostimulation Device for Treatment of Migraine Headache
This is a single-site, prospective, non-randomized and open label study to investigate the feasibility of home-use CVS for the prevention of episodic migraine headache and specifically to better understand what type of waveform…
- Trial name
- NCT01630044
- Testing
- TNM device
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Scion NeuroStim
Migraine
An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- COBRA (NCT05827887)
- Where
- 11 sites in Israel
- Volunteers
- 226 people
- Sponsor
- AbbVie
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE II (NCT02867709)
- Testing
- Ubrogepant
- Where
- 109 sites in United States
- Volunteers
- 1,686 people
- Sponsor
- Allergan
Migraine
Real-world Data Analysis of REN Treatment in Migraine Patients
Data analysis concerning four sets of metrics: A. Per-treatment patterns of REN use as a standalone treatment vs. in combination with medications. B.
- Trial name
- NCT04992897
- Testing
- Remote Electrical Neuromodulation (REN)
- Where
- 2 sites in United States, Israel
- Volunteers
- 12,151 people
- Sponsor
- Theranica
Migraine Disorders
A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.
This is a pharmacokinetic (PK) study designed to investigate a combination product containing sumatriptan succinate and naproxen sodium administered at 3 single doses (10mg sumatriptan/60mg naproxen sodium, 30mg sumatriptan/180mg…
- Trial name
- NCT00989625
- Testing
- This is a pharmacokinetic study (Treximet)
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Migraine With or Without Aura, Migraine
Cooling to Alleviate Migraine #3
This is a prospective, double-blind, sham-controlled, randomized, decentralized trial. This study aims to assess the safety and efficacy of the Mi-Helper transnasal cooling device for acute treatment of migraine in an at home…
- Conditions
- Migraine With or Without Aura, Migraine, Migraine Headache
- Trial name
- CALM3 (NCT06874361)
- Testing
- Mi-Helper
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Mi-Helper, Inc.
Migraine
A Study of the Effect of a Disease-Specific Migraine Smart Phone Application (App) on Participant Care
The purpose of this study is to determine whether using a smart phone application to foster communication between study participants and their doctor will impact care.
- Trial name
- NCT03559088
- Testing
- Migraine App
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Migraine
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
This study is an open-label, parallel group study to evaluate acute pulmonary safety and Pharmacokinetics (PK) of two doses, separated by 2 hours, of CVT-427 zolmitriptan inhalation powder in three groups of adults: those with…
- Trial name
- NCT02905227
- Testing
- CVT-427 (zolmitriptan inhalation powder)
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Acorda Therapeutics
Migraine Disorders
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- PROMISE 2 (NCT02974153)
- Testing
- ALD403 (Eptinezumab)
- Where
- 144 sites in United States, Belgium and 11 more
- Volunteers
- 1,121 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
Acute Treatment Trial in Adult Subjects With Migraines
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
- Trial name
- NCT03872453
- Testing
- Zavegepant, Intranasal Aptar Pharma Unit Dose System
- Where
- 82 sites in United States
- Volunteers
- 2,154 people
- Sponsor
- Pfizer
Headache (Migraine)
Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.
To determine whether a single dose of intravenous lornoxicam is superior to intravenous placebo for the acute treatment of moderate or severe headache associated with a single migraine attack in patients with a history of…
- Trial name
- NCT00293657
- Testing
- Lornoxicam 8 mg, Lornoxicam 16 mg
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- POZEN
Covid19
Efficacy of Adaptogens in Patients With Long COVID-19
The aim of this clinical trial of a fixed combination of standardized extracts from Rhodiola rosea roots, Schisandra chinensis berry and Eleutherococcus senticosus root (ADAPT-232) in COVID-19 patients is to demonstrate possible…
- Trial name
- NCT04795557
- Testing
- ADAPT-232 oral solution
- Where
- Georgia
- Volunteers
- 100 people
- Sponsor
- Swedish Herbal Institute AB